Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.

Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC.

Leukemia. 2018 Feb 22. doi: 10.1038/s41375-018-0062-8. [Epub ahead of print]

PMID:
29487385
2.

The proteasome and proteasome inhibitors in multiple myeloma.

Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG.

Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8. Review.

PMID:
29196868
3.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC.

Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.

4.

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC.

Oncotarget. 2017 Jul 5;8(46):80109-80123. doi: 10.18632/oncotarget.19019. eCollection 2017 Oct 6.

5.

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.

Ray A, Das DS, Song Y, Hideshima T, Tai YT, Chauhan D, Anderson KC.

Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6. No abstract available.

PMID:
29104288
6.

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.

Bae J, Hideshima T, Zhang GL, Zhou J, Keskin DB, Munshi NC, Anderson KC.

Leukemia. 2018 Mar;32(3):752-764. doi: 10.1038/leu.2017.316. Epub 2017 Nov 1.

7.

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J.

Br J Haematol. 2017 Dec;179(5):756-771. doi: 10.1111/bjh.14974. Epub 2017 Oct 19.

PMID:
29048129
8.

MUC1-C is a target in lenalidomide resistant multiple myeloma.

Yin L, Tagde A, Gali R, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Br J Haematol. 2017 Sep;178(6):914-926. doi: 10.1111/bjh.14801. Epub 2017 Jun 23.

PMID:
28643330
9.

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.

Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, Tai YT, Mazitschek R, Hideshima T, Anderson KC.

Leukemia. 2017 Dec;31(12):2670-2677. doi: 10.1038/leu.2017.144. Epub 2017 May 11.

10.

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival.

Ohguchi H, Harada T, Sagawa M, Kikuchi S, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2017 Dec;31(12):2661-2669. doi: 10.1038/leu.2017.141. Epub 2017 May 10.

11.

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC.

Clin Cancer Res. 2017 Sep 1;23(17):5225-5237. doi: 10.1158/1078-0432.CCR-17-0263. Epub 2017 Apr 25.

PMID:
28442502
12.

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC.

Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12.

13.

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.

Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner JE.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13162-13167. Epub 2016 Oct 31.

14.

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.

Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T, Joo J, Kong SY, Szalat RE, Richardson PG, Munshi NC, Dorfman DM, Anderson KC.

Oncotarget. 2016 Nov 22;7(47):77326-77341. doi: 10.18632/oncotarget.12643.

15.

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Cea M, Cagnetta A, Acharya C, Acharya P, Tai YT, Yang C, Lovera D, Soncini D, Miglino M, Fraternali-Orcioni G, Mastracci L, Nencioni A, Montecucco F, Monacelli F, Ballestrero A, Hideshima T, Chauhan D, Gobbi M, Lemoli RM, Munshi N, Treon SP, Anderson KC.

Clin Cancer Res. 2016 Dec 15;22(24):6099-6109. Epub 2016 Jun 10.

16.

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.

Harada T, Hideshima T, Anderson KC.

Int J Hematol. 2016 Sep;104(3):300-9. doi: 10.1007/s12185-016-2008-0. Epub 2016 Apr 20. Review.

PMID:
27099225
17.

MUC1-C drives MYC in multiple myeloma.

Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Blood. 2016 May 26;127(21):2587-97. doi: 10.1182/blood-2015-07-659151. Epub 2016 Feb 23.

18.

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.

Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC.

Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258.

19.

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.

Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC.

Blood. 2016 Mar 3;127(9):1138-50. doi: 10.1182/blood-2015-06-649970. Epub 2015 Dec 16.

20.

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.

Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC.

PLoS One. 2015 Dec 2;10(12):e0143847. doi: 10.1371/journal.pone.0143847. eCollection 2015.

21.

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P.

Clin Cancer Res. 2016 Mar 1;22(5):1222-33. doi: 10.1158/1078-0432.CCR-15-0489. Epub 2015 Nov 2.

22.

Novel therapeutic strategies for multiple myeloma.

Mimura N, Hideshima T, Anderson KC.

Exp Hematol. 2015 Aug;43(8):732-41. doi: 10.1016/j.exphem.2015.04.010. Epub 2015 Jun 26. Review.

23.

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, Anderson KC, Tonon G.

Cancer Discov. 2015 Sep;5(9):972-87. doi: 10.1158/2159-8290.CD-14-0943. Epub 2015 Jun 16.

24.

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD.

Nat Med. 2015 Jun;21(6):572-80. doi: 10.1038/nm.3867. Epub 2015 May 25.

25.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC.

Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15.

26.

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.

Hideshima T, Cottini F, Ohguchi H, Jakubikova J, Gorgun G, Mimura N, Tai YT, Munshi NC, Richardson PG, Anderson KC.

Blood Cancer J. 2015 May 15;5:e312. doi: 10.1038/bcj.2015.38.

27.

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.

Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, Jakubikova J, Bianchi G, Harada T, Gorgun G, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2015 Sep;29(9):1918-27. doi: 10.1038/leu.2015.83. Epub 2015 Mar 24.

PMID:
25801913
28.

Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.

Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dančík V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MA, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL.

Cell Rep. 2015 Feb 4. pii: S2211-1247(15)00030-3. doi: 10.1016/j.celrep.2015.01.017. [Epub ahead of print]

29.

Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.

Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Alves NJ, Suzuki R, Kikuchi S, Hideshima T, Anderson KC, Kiziltepe T, Bilgicer B.

J Control Release. 2014 Dec 28;196:113-21. doi: 10.1016/j.jconrel.2014.10.005. Epub 2014 Oct 12.

PMID:
25312543
30.

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.

Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC.

Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. No abstract available.

31.

Novel targeted agents in the treatment of multiple myeloma.

Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC, Richardson PG.

Hematol Oncol Clin North Am. 2014 Oct;28(5):903-25. doi: 10.1016/j.hoc.2014.07.001. Epub 2014 Aug 5. Review.

PMID:
25212889
32.

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.

Mol Cancer Ther. 2014 Nov;13(11):2489-500. doi: 10.1158/1535-7163.MCT-14-0147. Epub 2014 Aug 29.

33.

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC.

Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16.

34.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G.

Nat Med. 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. Epub 2014 May 11.

35.

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.

Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS.

Br J Haematol. 2014 Aug;166(3):401-9. doi: 10.1111/bjh.12909. Epub 2014 Apr 25.

PMID:
24761838
36.

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.

Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, Tao J, Tai YT, Treon S, Pinkus G, Kuo WP, Hideshima T, Bouxsein M, Munshi N, Anderson K, Carrasco R.

Cancer Res. 2014 Mar 15;74(6):1801-13. doi: 10.1158/0008-5472.CAN-13-3311-T. Epub 2014 Mar 5.

37.

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T.

Int J Oncol. 2014 Apr;44(4):1171-6. doi: 10.3892/ijo.2014.2273. Epub 2014 Jan 23.

38.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.

Blood. 2014 Mar 6;123(10):1461-9. doi: 10.1182/blood-2013-07-517276. Epub 2014 Jan 15.

39.

Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.

Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A, Lee AH, Dranoff G, Anderson KC, Munshi NC.

Oncoimmunology. 2014 Dec 2;3(12):e970914. eCollection 2014.

40.

Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.

Hideshima T, Mazitschek R, Santo L, Mimura N, Gorgun G, Richardson PG, Raje N, Anderson KC.

Leukemia. 2014 Feb;28(2):457-60. doi: 10.1038/leu.2013.301. Epub 2013 Oct 22. No abstract available.

41.

Clinical translation in multiple myeloma: from bench to bedside.

Laubach J, Hideshima T, Richardson P, Anderson K.

Semin Oncol. 2013 Oct;40(5):549-53. doi: 10.1053/j.seminoncol.2013.07.009. Review.

PMID:
24135399
42.

Phase transitions in human IgG solutions.

Wang Y, Lomakin A, Latypov RF, Laubach JP, Hideshima T, Richardson PG, Munshi NC, Anderson KC, Benedek GB.

J Chem Phys. 2013 Sep 28;139(12):121904. doi: 10.1063/1.4811345.

43.

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.

Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5.

44.

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3.

45.

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N.

Leukemia. 2013 Dec;27(12):2366-75. doi: 10.1038/leu.2013.194. Epub 2013 Jun 28.

46.

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD Jr, Anderson KC, Carrasco DR.

Br J Haematol. 2013 Jul;162(2):210-20. doi: 10.1111/bjh.12365. Epub 2013 May 7.

47.

Histone deacetylase inhibitors in the treatment for multiple myeloma.

Hideshima T, Anderson KC.

Int J Hematol. 2013 Mar;97(3):324-32. doi: 10.1007/s12185-013-1290-3. Epub 2013 Mar 10.

PMID:
23475757
48.

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N.

Bone. 2013 Apr;53(2):487-96. doi: 10.1016/j.bone.2013.01.012. Epub 2013 Jan 17.

49.

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC.

Blood. 2013 Apr 11;121(15):2975-87. doi: 10.1182/blood-2012-08-448548. Epub 2013 Jan 15.

50.

New proteasome inhibitors in myeloma.

Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG.

Curr Hematol Malig Rep. 2012 Dec;7(4):258-66. doi: 10.1007/s11899-012-0141-2. Review.

PMID:
23065395

Supplemental Content

Loading ...
Support Center